Results 141 to 150 of about 20,430,225 (174)
Some of the next articles are maybe not open access.
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review
Clinical Genitourinary Cancer, 2019Pazopanib is a protein tyrosine kinase inhibitor that limits tumor growth through angiogenesis inhibition. The use of other protein tyrosine kinase inhibitors, specifically sunitinib, within non-clear cell renal cell carcinoma (nccRCC) has led to increased survival with a decreased adverse event profile. The data for the treatment of nccRCC is limited,
Gregory T, Sneed +3 more
openaire +2 more sources
Treatment for Non-clear Cell Renal Cell Carcinoma
2017Non-clear cell (NCC) renal cell carcinoma (RCC) is less common and accounts for 25 % of all patients with metastatic RCC. Metastatic NCCRCC and clear cell (CC) RCC both respond infrequently to cytotoxic and cytokine therapy; however, compared with CCRCC patients, NCCRCC patients have a poorer prognosis.
openaire +1 more source
Metastatic non‐clear cell renal cell carcinoma: current therapeutic options
BJU International, 2008Non‐clear cell (ncc) renal cell carcinoma (RCC) accounts for ≈25% of all patients with metastatic RCC. It is refractory to standard immuno(chemo)therapy and, to date, no specific trials have been reported to evaluate the efficacy of novel targeted drugs in the different subtypes of metastatic nccRCC.
Andres J, Schrader +4 more
openaire +2 more sources
Molecular and therapeutic landscape of non-clear cell renal carcinoma
Nature Reviews UrologyNon-clear cell renal cell carcinomas (nccRCC) include diverse subtypes such as papillary, oncocytic and chromophobe, collecting duct, molecularly defined and other rare histological subtypes, each associated with unique clinical, pathological, genetic and molecular features as well as therapeutic challenges.
Prerna R. Nepali +6 more
openaire +2 more sources
Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non–Clear Cell Renal Cell Carcinoma
European Urology, 2010A 35-year-old woman presented with a 12-cm right renal mass with retroperitoneal lymph node involvement and pulmonary and bone metastases. Renal mass biopsy revealed an unclassified high-grade non-clear cell renal cell carcinoma (RCC) with eosinophilic cells. Due to the extent of the disease, neoadjuvant temsirolimus was initiated.
Faba, OR +6 more
openaire +3 more sources
Outcomes of Patients With Metastatic Non–Clear-Cell Renal Cell Carcinoma Treated With Pazopanib
Clinical Genitourinary Cancer, 2017Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non-clear-cell RCC, but data on outcomes in this setting are limited.We conducted a retrospective data analysis of records of consecutive metastatic non-clear ...
Matrana, Marc R. +12 more
openaire +5 more sources
Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
Journal of Oncology Pharmacy PracticeObjective Renal cell carcinoma (RCC) is the most common kidney cancer, with clear cell RCC being the predominant subtype. However, non-clear cell RCC constitutes a significant proportion of cases, presenting distinct challenges in treatment due to its varied histological subtypes.
Balqees Ara +7 more
openaire +2 more sources
[Clinical analysis of non-clear cell renal cell carcinoma].
Hinyokika kiyo. Acta urologica Japonica, 2015Clinicopathological features and prognosis of metastatic renal cell carcinoma (mRCC) vary by histopathological type. In this study, we analyzed these relationships with regard to non-clear cell RCC (nccRCC). We also analyzed the therapeutic trends for patients with mRCC.
Kojiro, Ohba +6 more
openaire +1 more source